Anzeige
Mehr »
Dienstag, 29.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4142V | ISIN: US48669G3039 | Ticker-Symbol:
NASDAQ
28.07.25 | 22:00
8,570 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
AUSTRALIEN
1-Jahres-Chart
KAZIA THERAPEUTICS LIMITED ADR Chart 1 Jahr
5-Tage-Chart
KAZIA THERAPEUTICS LIMITED ADR 5-Tage-Chart

Aktuelle News zur KAZIA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrKAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer2
10.07.Kazia Therapeutics stock price target raised to $13 from $2 at H.C. Wainwright-
09.07.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
09.07.Kazia Reports Over 50% Cancer Cell Reduction In Early Data From Breast Cancer Trial, Stock Jumps3
09.07.Kazia Therapeutics stock soars after positive early cancer treatment data6
KAZIA THERAPEUTICS Aktie jetzt für 0€ handeln
09.07.Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase ...149SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial...
► Artikel lesen
11.06.Paxalisib von Kazia zeigt vielversprechende Ergebnisse in präklinischer Brustkrebsstudie13
11.06.Kazia Therapeutics Limited: Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)237SYDNEY, June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics...
► Artikel lesen
05.06.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
05.06.Kazia Therapeutics Limited: Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer208Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve...
► Artikel lesen
28.05.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer2
15.05.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer-
15.04.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer10
31.03.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
31.03.Kazia Therapeutics sells intellectual property and trademarks rights for Cantrixil1
31.03.Kazia Therapeutics sells Cantrixil rights for $1 million3
31.03.Vivesto AB: Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rights275Solna, Sweden, March 31, 2025 - Vivesto AB, an oncology-focused development company, today announced that it has signed an agreement with the Australian pharmaceutical company Kazia Therapeutics to...
► Artikel lesen
13.03.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
20.02.KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer1
20.02.Kazia erforscht Paxalisib für Parkinson mit Förderung der Michael J. Fox Foundation7
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1